ACADIA Pharmaceuticals Inc Announces Positive Top-line Results Call Transcript
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call. My name is Towanda, and I will be your coordinator for today. (Operator Instructions)
I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations of ACADIA. You may proceed.
Thank you, Towanda. Good afternoon, and thank you for joining us on today's call to discuss the positive top line results from the pivotal Phase III LAVENDER study evaluating trofinetide as a potential treatment for Rett syndrome. On today's call, Steve Davis, our CEO; and Serge Stankovic, our President, will provide some opening remarks. Following Serge, we will hear from Dr. Dominique Pichard, Chief Scientific Officer at the International Rett Syndrome Foundation, who will discuss Rett syndrome and the unmet need in greater detail. Then Kathie Bishop, our Chief Scientific Officer and Head of Rare Disease, will walk us through the LAVENDER results. Finally, Steve Davis will provide some closing
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |